Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12619000971134
Ethics application status
Approved
Date submitted
3/06/2019
Date registered
9/07/2019
Date last updated
19/01/2024
Date data sharing statement initially provided
9/07/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
ERUPT Trial: Urethral scarring after radiation treatment for prostate cancer
Scientific title
ERUPT Trial: External beam Radiotherapy and Urethral strictures in Prostate cancer Treatment
Secondary ID [1] 298404 0
Nil known
Universal Trial Number (UTN)
U1111-1234-6138
Trial acronym
ERUPT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prostate Cancer 313106 0
Urethral Strictures 313107 0
Condition category
Condition code
Cancer 311585 311585 0 0
Prostate
Renal and Urogenital 311820 311820 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Uroflow measurements at baseline, 6 weeks post end of radiation therapy treatment and then every 6 months for 5 years post radiation treatment for prostate cancer.
AUA surveys completed at baseline, 6 weeks post end of radiation therapy treatment and then every 6 months for 5 years post radiation treatment.
Radiation oncologists or a member of the study team will perform uroflow measurements at each follow up appointment and input data into database.
Each uroflow measurement takes approximately 5-10 minutes to complete.
This follow up will be performed at the radiation oncology centre in Toowoomba via face-to-face appointments.
Intervention code [1] 314650 0
Early Detection / Screening
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 320294 0
Incidence of urethral strictures post radiation treatment for prostate cancer by monitoring post-radiotherapy uroflow measurements and patients AUA survey scores.
Timepoint [1] 320294 0
At 6 weeks post end of radiation therapy treatment and at at 6-month intervals up to 5 years post-radiation therapy
Secondary outcome [1] 371086 0
Incidence of other urinary morbidities as a consequence of radiation therapy for prostate cancer. (i.e, dysuria, urinary frequency, nocturia, haematuria). This will be assessed via the AUA surveys that patients complete.
Timepoint [1] 371086 0
At 6 weeks post end of radiation therapy treatment and at at 6-month intervals up to 5 years post-radiation therapy

Eligibility
Key inclusion criteria
All adult men >18 years of age who undergo external beam radiotherapy for prostate cancer between August 2020 and July 2023
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
Men who have previously had pelvic external beam radiatiotherapy for other cancers
Men who have had previous urethral strictures or treatment for urethral strictures.

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Defined population
Timing
Prospective
Statistical methods / analysis
We estimate that we see approximately 350 patients with prostate cancer who receive radiation therapy in a year. The recruitment target for this study is defined by the number of
patients recruited during August 2020 until July 2023.
Patient AUA survey scores and uroflow measurements will be collated and compared against the dosages of radiotherapy to see if certain dosages predispose to the development of urethral strictures.
Patients will then be stratified into 3 outcome groups: no strictures, short term strictures (1-2 years) and long term strictures (3-5 years).
Confounding factors will be initially controlled for then multivariate analysis will be conducted to see if these factors can also predispose to urethral strictures.
Data will be collated in the form of a research paper. Preliminary results will be available after 3 years and may be presented at international conferences.
Target audience will be urologists, radiation oncologists, nurses, trainees, medical students and allied health professionals.
Data will be of mixed categorical and continuous type. The AUA surveys ask that patients rate their symptoms on a score of 0-5 with each question. Scores of 0-7 are classified as mild, 8-19 indicates moderate symptom severity and 20-35 indicates severe symptoms. Uroflow measurements look at the voiding time, flow time, maximum flow rate and volume voided. These are continuous measurements

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
1/08/2019
Actual
26/08/2020
Date of last participant enrolment
Anticipated
30/07/2024
Actual
Date of last data collection
Anticipated
30/09/2028
Actual
Sample size
Target
350
Accrual to date
73
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 13898 0
Toowoomba Hospital - Toowoomba
Recruitment hospital [2] 13899 0
St Andrew's Toowoomba Hospital - Toowoomba
Recruitment hospital [3] 21410 0
Icon Cancer Centre Toowoomba - Toowoomba
Recruitment postcode(s) [1] 26671 0
4350 - Toowoomba

Funding & Sponsors
Funding source category [1] 302944 0
Charities/Societies/Foundations
Name [1] 302944 0
Icon Cancer Foundation
Country [1] 302944 0
Australia
Primary sponsor type
Charities/Societies/Foundations
Name
Icon Cancer Foundation
Address
Level 1/ 22 Cordelia Street, South Brisbane QLD 4101
Country
Australia
Secondary sponsor category [1] 302910 0
None
Name [1] 302910 0
Address [1] 302910 0
Country [1] 302910 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 303506 0
Darling Downs Hospital and Health Service Human Research Ethics Committee
Ethics committee address [1] 303506 0
Ethics committee country [1] 303506 0
Australia
Date submitted for ethics approval [1] 303506 0
05/03/2019
Approval date [1] 303506 0
20/03/2019
Ethics approval number [1] 303506 0
LNR/19/QTDD/47713

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 93902 0
Dr Lekshmi Nair
Address 93902 0
Icon Cancer Centre Toowoomba, 280 North Street Toowoomba QLD 4350
Country 93902 0
Australia
Phone 93902 0
+61 07 4614 5800
Fax 93902 0
Email 93902 0
[email protected]
Contact person for public queries
Name 93903 0
Lloyd Smyth
Address 93903 0
Level 1/ 22 Cordelia Street, South Brisbane QLD 4101
Country 93903 0
Australia
Phone 93903 0
+61 7 3737 4500
Fax 93903 0
Email 93903 0
[email protected]
Contact person for scientific queries
Name 93904 0
Devang Desai
Address 93904 0
Toowoomba Hospital
Urology Department
154 Pechey Street
Toowoomba QLD 4350
Country 93904 0
Australia
Phone 93904 0
+61 7 4632 8481
Fax 93904 0
Email 93904 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.